Open AccessP1276: DOSE RESPONSE PROFILE OF IGM‐2323, A CD20XCD3 IGM BISPECIFIC T CELL ENGAGER, IN TRANSLATIONAL MODELS SUPPORTS PHASE 2 DOSE SELECTION IN NON‐HODGKIN'S LYMPHOMA
Author(s) -
Leabman M. K.,
Hernandez G.,
Ng C. M.,
Tang J.,
Pandya D.,
Hart K. C.,
Li K.,
Hinton P. R.,
So J.,
Qazi I.,
Cheah C. Y.,
Kim W. S.,
Budde E.,
Gopal A. K.,
Manley T.,
Takimoto C. H.,
Sinclair A. M.,
Carroll S. F.,
Keyt B. A.,
Kotturi M. F.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847968.95263.25
Subject(s) - cd8 , immune system , t cell , cd20 , immunology , cancer research , antibody , chemistry , medicine